| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-03-23 | PTC Therapeutics (USA - NJ) | restructuring |
Rare diseases - Genetic diseases | Restructuring | ||
| 2016-03-21 | Onxeo (France) | establishment of a new subsidiary in the US |
Cancer - Oncology - Rare diseases | Establishment of a new subsidiary in the US | ||
| 2016-03-21 | Adocia (France) | nomination |
Metabolic diseases | Nomination | ||
| 2016-03-21 | Cellectis (France) Takara Bio (Japan) | recombinant human fibronectin fragment RetroNectin® | licensing supply |
Technology - Services | Licensing agreement | |
| 2016-03-21 | Molmed (Italy) Genenta Science (Italy) | gene therapy product for the treatment of multiple myeloma | multiple myeloma | development manufacturing production collaboration |
Cancer - Oncology - Rare diseases | Development agreement |
| 2016-03-21 | Ultragenyx Pharmaceutical (USA - CA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-03-21 | Novasep (France) GTP Technology (France) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2016-03-21 | GlycoMimetics (USA - Md) | nomination | Cancer - Oncology | Nomination | ||
| 2016-03-21 | Autolus (UK) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2016-03-18 | Eisai (Japan) Helsinn (Switzerland) | Akynzeo® (oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (NEPA)) Aloxi® (palonosetron HCl) | prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following both highly and moderately emetogenic chemotherapy | distribution |
Digestive diseases - Gastrointestinal diseases - Inflammatory diseases | Distribution agreement |
| 2016-03-17 | Huawei (China) WuXi AppTec (China) WuXi NextCODE (China) | state-of the-art precision medicine cloud platform | collaboration |
Technology - Services | Collaboration agreement | |
| 2016-03-17 | Galapagos (Belgium) Thrombogenics (Belgium) | integrin antagonists | diabetic eye disease | licensing |
Ophtalmological diseases | Licensing agreement |
| 2016-03-17 | Kymab (UK) | nomination |
Nomination | |||
| 2016-03-17 | Transgene (France) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2016-03-17 | GSK (UK) | nomination |
Nomination | |||
| 2016-03-17 | GSK (UK) | resignation |
Resignation | |||
| 2016-03-17 | Zambon (Italy) US WorldMeds (USA - KY) | Xadago™ (safinamide) | add-on therapy to a stable dose of a single dopamine agonist in early Parkinson’s disease patients add-on therapy to levodopa alone or in combination with other Parkinson’s disease treatments in mid-to late stage Parkinson’s disease patients | commercialisation |
Neurodegenerative diseases | Commercialisation agreement |
| 2016-03-17 | Zambon (Italy) Newron Pharmaceuticals (Italy) US WorldMeds (USA - KY) | Xadago™ | add-on therapy to a stable dose of a single dopamine agonist in early Parkinson’s disease patients add-on therapy to levodopa alone or in combination with other Parkinson’s disease treatments in mid-to late stage Parkinson’s disease patients | commercialisation |
Neurodegenerative diseases - CNS diseases | Commercialisation agreement |
| 2016-03-17 | Kite Pharma (USA - CA) Roche (Switzerland) | axicabtagene ciloleucel (KTE-C19 (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) and atezolizumab | refractory, aggressive non-Hodgkin lymphoma (NHL) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-03-16 | Johnson & Johnson Innovation, Janssen Pharmaceuticals, a J&J company (USA - NJ) | JLINX | establishment of a new subsidiary in the EU |
Establishment of a new subsidiary in the EU |
